Next-generation sequencing-based testing for cancer mutational landscape diversity: Clinical implications?

摘要

Although tumor cell heterogeneity was described 30 years ago [l], solid evidence of patient-to-patient and intratumor genetic diversity could only recently be provided based on high-throughput (HT) next-generation sequencing (NGS) technologies [2-4]. This genome diversity assessment now paves the way for novel mutational landscape-based cancer classification [5] and clinical personalized genomic medicine [6].